Last reviewed · How we verify
SABER-Bupivacaine Treatment 2a
SABER-Bupivacaine Treatment 2a is a Small molecule drug developed by Durect. It is currently in Phase 2 development.
At a glance
| Generic name | SABER-Bupivacaine Treatment 2a |
|---|---|
| Sponsor | Durect |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery (PHASE2)
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SABER-Bupivacaine Treatment 2a CI brief — competitive landscape report
- SABER-Bupivacaine Treatment 2a updates RSS · CI watch RSS
- Durect portfolio CI
Frequently asked questions about SABER-Bupivacaine Treatment 2a
What is SABER-Bupivacaine Treatment 2a?
SABER-Bupivacaine Treatment 2a is a Small molecule drug developed by Durect.
Who makes SABER-Bupivacaine Treatment 2a?
SABER-Bupivacaine Treatment 2a is developed by Durect (see full Durect pipeline at /company/durect).
What development phase is SABER-Bupivacaine Treatment 2a in?
SABER-Bupivacaine Treatment 2a is in Phase 2.
Related
- Manufacturer: Durect — full pipeline
- Compare: SABER-Bupivacaine Treatment 2a vs similar drugs
- Pricing: SABER-Bupivacaine Treatment 2a cost, discount & access